Vaxcyte (PCVX) Assets Average (2020 - 2026)

Vaxcyte (PCVX) has reported Assets Average for 7 consecutive years, with $3.2 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Assets Average fell 7.81% year-over-year to $3.2 billion; the TTM figure through Mar 2026 stood at $3.2 billion (down 7.81% YoY), while the FY2025 annual figure was $3.3 billion, up 32.42% from the prior year.
• Assets Average rose to $3.2 billion in Q1 2026 per PCVX's latest filing, from $3.1 billion in the prior quarter.
• Across five years, Assets Average topped out at $3.5 billion in Q4 2024 and bottomed at $363.5 million in Q1 2022.
• Historically, Assets Average has averaged $2.0 billion across 5 years, with a median of $1.7 billion in 2024.
• Annual changes were most pronounced in 2023 — Assets Average soared 264.08% — and 2025, when it decreased 12.68%.
• Vaxcyte's Assets Average stood at $709.1 million in 2022, then surged by 104.76% to $1.5 billion in 2023, then soared by 143.5% to $3.5 billion in 2024, then fell by 12.68% to $3.1 billion in 2025, then grew by 2.86% to $3.2 billion in 2026.
• Business Quant data shows PCVX's Assets Average at $3.2 billion in Q1 2026, $3.1 billion in Q4 2025, and $3.2 billion in Q3 2025.